A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

CompletedOBSERVATIONAL
Enrollment

6,917

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

October 1, 2020

Study Completion Date

October 1, 2020

Conditions
Acute Myeloid Leukemia
Trial Locations (22)

Unknown

Hospital General Universitario de Albacete, Albacete

Hospital General Universitario de Alicante, Alicante

Hospital Germans Trias i Pujol-ICO, Badalona

Hospital Universitario de Burgos, Burgos

Hospital General Universitario de Castellón, Castellon

Hospital San Pedro de Alcántara, Cáceres

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria

Hospital Universitario de León, León

Hospital Universitario Lucus Augusti, Lugo

Hospital Clínico San Carlos, Madrid

Hospital Univeristario Ramón y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

Hospital General Universitario Morales Meseguer, Murcia

Hospital Universitario Central Asturias, Oviedo

Clínica Universitaria de Navarra, Pamplona

Hospital Universitario de Salamanca, Salamanca

Hospital Universitario Virgen del Rocío, Seville

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitari I Politécnic La Fe, Valencia

Hospital Universitario Doctor Peset, Valencia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

PETHEMA Foundation

OTHER

NCT05541224 - A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers | Biotech Hunter | Biotech Hunter